Evolva Holding SA (EVE.SW)

CHF 0.84

(-6.44%)

EBITDA Summary of Evolva Holding SA

  • Evolva Holding SA's latest annual EBITDA in 2023 was -98.35 Million CHF , up 137.41% from previous year.
  • Evolva Holding SA's latest quarterly EBITDA in 2024 Q2 was 1.34 Million CHF , down 0.0% from previous quarter.
  • Evolva Holding SA reported an annual EBITDA of -34.51 Million CHF in 2022, up 34.47% from previous year.
  • Evolva Holding SA reported an annual EBITDA of -31.82 Million CHF in 2021, down -77.39% from previous year.
  • Evolva Holding SA reported a quarterly EBITDA of -6.28 Million CHF for 2023 Q2, down 0.0% from previous quarter.
  • Evolva Holding SA reported a quarterly EBITDA of 13.41 Million CHF for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of Evolva Holding SA (2023 - 2005)

Historical Annual EBITDA of Evolva Holding SA (2023 - 2005)

Year EBITDA EBITDA Growth
2023 -98.35 Million CHF 137.41%
2022 -34.51 Million CHF 34.47%
2021 -31.82 Million CHF -77.39%
2020 -20.6 Million CHF -6.97%
2019 -13.18 Million CHF 47.41%
2018 -23.47 Million CHF 37.89%
2017 -37.59 Million CHF -10.7%
2016 -33.45 Million CHF -17.97%
2015 -28.48 Million CHF -51.49%
2014 -19.28 Million CHF -32.8%
2013 -14.1 Million CHF 26.27%
2012 -14.09 Million CHF 17.25%
2011 -19.19 Million CHF -22.55%
2010 -20 Million CHF -204.7%
2009 -6.28 Million CHF 88.09%
2008 -52.75 Million CHF 7.85%
2007 -57.24 Million CHF 18.95%
2006 -70.63 Million CHF -110.24%
2005 -33.6 Million CHF 0.0%

Peer EBITDA Comparison of Evolva Holding SA

Name EBITDA EBITDA Difference
Addex Therapeutics Ltd -10.22 Million CHF -861.586%
BB Biotech AG -201.25 Million CHF 51.128%
Basilea Pharmaceutica AG 29.49 Million CHF 433.471%
Idorsia Ltd -254.55 Million CHF 61.36%
Kuros Biosciences AG -10.4 Million CHF -844.927%
Molecular Partners AG -59.51 Million CHF -65.265%
Relief Therapeutics Holding AG -108.2 Million CHF 9.098%
Santhera Pharmaceuticals Holding AG 79.17 Million CHF 224.229%